Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Immatics’ second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of…
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of…
GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies I…